title: Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
abstract: Thirty patients were investigated with hyperlipoproteinaemia, 15 patients with non-insulin dependent diabetes mellitus (NIDDM) and 15 with primary hyperlipoproteinaemia. The patients took 250 mg acipimox (5-metyl-pyrazine-carboxylic acid 4-oxide) 3 times per day for 2 months. Serum examinations were performed before and after 1 and 2 months of acipimox administration. After treatment the cholesterol and triglyceride levels decreased in both groups. Patients with NIDDM had 11% increase of high density lipoprotein-cholesterol (HDL-C) level at the end of the first, and 18% increase at the end of the second month, while patients with primary hyperlipoproteinaemia did not change significantly. The low density lipoprotein (LDL) level did not change significantly in either groups of patients. The apolipoprotein A 1 (apo A 1) levels increased significantly during the second month of acipimox administration. Uric acid levels decreased in both groups, but significant change could be detected mainly in the NIDDM group. Serum glucose level did not change in the non-diabetic patients, while it decreased significantly in the NIDDM group.
authors.affiliation: 1st Department of Internal Medicine, University Medical School of Debrecen, Hungary.
authors.forename: G
authors.initials: G
authors.lastname: Paragh
authors.forename: Z
authors.initials: Z
authors.lastname: Balogh
authors.forename: J
authors.initials: J
authors.lastname: Boda
authors.forename: P
authors.initials: P
authors.lastname: Kovács
authors.forename: L
authors.initials: L
authors.lastname: Kárpáti
authors.forename: J
authors.initials: J
authors.lastname: Szabó
authors.forename: A
authors.initials: A
authors.lastname: Leövey
mesh_terms: D016632:Apolipoprotein A-I / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*; D013997:Time Factors; D014280:Triglycerides / Q000627:therapeutic use; D014527:Uric Acid / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001786:Blood Glucose; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D011719:Pyrazines; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; C027696:acipimox